Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)

Next Previous
Search
Trial Profile

Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing (A Prospective, Open-label, Multi-center, Phase II Platform Study)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Bevacizumab (Primary) ; Camrelizumab (Primary) ; Dalpiciclib (Primary) ; Everolimus (Primary) ; Exemestane (Primary) ; Famitinib (Primary) ; Fulvestrant (Primary) ; Fuzuloparib (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; SHR 1167 (Primary) ; SHR 6209 (Primary) ; SHR A2102 (Primary) ; SHR-A1921 (Primary) ; SHR-A2009 (Primary) ; Sorafenib (Primary) ; Trastuzumab rezetecan (Primary) ; Capecitabine; Paclitaxel; Phosphatidylinositol 3 kinase alpha inhibitors; Rivoceranib; Vinorelbine
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms Linux

Most Recent Events

  • 04 Oct 2024 Arms increased from 8 to 26. Drugs SHR-A1811, bevacizumab, SHR-6209, SHR-A1921, SHR-A2009, and SHR-A2102 added newly in the trial.
  • 04 Oct 2024 Planned number of patients changed from 140 to 620.
  • 02 Jan 2023 Planned initiation date changed from 1 Dec 2022 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top